IDSA 2025 指南:免疫功能低下患者季节性 RSV 感染预防疫苗使用
美国感染病学会(IDSA)召集多学科专家组,基于 2024 年 8 月至 2025 年 7 月的系统综述及 GRADE 方法,制定免疫功能低下成人和儿童季节性 RSV 疫苗接种快速建议。两项测试阴性病例对照研究显示成人接种可减少 RSV 相关住院 70%(95%CI:66%-73%),专家组对免疫功能低下成人及青少年给出强推荐,对 18 岁以下患者建议共同决策。
要点
- 免疫功能低下成人及青少年强烈推荐按年龄接种 RSV 疫苗。
- 18 岁以下免疫功能低下者建议共同决策后接种。
- 接种时机应个体化,考虑治疗周期、移植状态及 B 细胞清除治疗。
核心结论
- 免疫功能低下成人及青少年接种 RSV 疫苗可大幅减少重症,严重危害可能性低,专家组给出强推荐。
- 18 岁以下免疫功能低下患者建议在共同决策后接种 RSV 疫苗。
研究设计与样本
- IDSA 召集多学科专家组制定快速循证建议,系统综述 2024 年 8 月至 2025 年 7 月发表的比较效果与危害数据,并补充 Vaccine Integrity Project 证据。
- 采用 GRADE 方法评估证据确定性及推荐强度。
主要发现
- 两项免疫功能低下成人的测试阴性病例对照研究显示,接种疫苗使 RSV 相关住院减少 70%(95%CI:66%-73%)。
- 来自老年人群的间接证据显示,疫苗对危重疾病的有效性为 81%(95%CI:52%-92%)。
- 三项随机试验中,接种组与未接种组严重不良事件相当。
- 吉兰-巴雷综合征罕见,估计每百万剂次增加 11 例。
关键数值与推荐
- 对免疫功能低下成人及青少年,强烈推荐按年龄接种 RSV 疫苗。
- 对 18 岁以下免疫功能低下患者,建议共同决策。
- 接种时机应依亚组个体化,考虑治疗周期、移植状态及 B 细胞清除治疗。
- 符合条件的家庭成员应保持最新接种;RSV 疫苗可与流感疫苗及 COVID-19 疫苗同时接种。
临床怎么用
- 感染科医生应对免疫功能低下成人及青少年常规评估并推荐按年龄接种 RSV 疫苗。
- 对 18 岁以下免疫功能低下患者,应与家属共同决策后决定是否接种。
- 接种时机需结合患者治疗周期、移植状态及 B 细胞清除治疗个体化安排。
- 可同时接种流感疫苗和 COVID-19 疫苗,并建议符合条件的家庭成员保持最新接种。
局限性
- 免疫功能低下人群的直接证据仍有限。
- 部分证据来自老年人群的间接数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunocompromised individuals experience disproportionately severe outcomes from respiratory syncytial virus (RSV) infection, yet direct evidence to guide vaccination in this population remains limited. To support clinical and shared decision-making for the 2025-2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary expert panel to develop rapid, evidence-based recommendations on RSV vaccination among immunocompromised adults and children. The panel conducted a systematic review of comparative effectiveness and harms data published between August 2024 and July 2025, supplemented by additional evidence from the Vaccine Integrity Project. Certainty of evidence and recommendation strength were assessed using the GRADE approach. Two test-negative case-control studies in immunocompromised adults showed vaccination reduced RSV-associated hospitalization by 70% (95% CI: 66%-73%). Indirect evidence from older-adult populations demonstrated 81% effectiveness (95% CI: 52%-92%) against critical illness. Across three randomized trials, serious adverse events were comparable between vaccinated and unvaccinated groups. Guillain-Barré syndrome was rare, with an estimated 11 excess cases per million doses. Given substantial reduction in severe disease and low likelihood of serious harm, the panel issued a strong recommendation for age-appropriate RSV vaccination in adults and adolescents with compromised immunity. For immunocompromised patients <18 years, shared decision-making is advised. Timing should be individualized by subgroups, considering treatment cycles, transplant status, and B-cell-depleting therapies. Household members should remain up to date when eligible, and coadministration with influenza and coronavirus disease 2019 vaccines is acceptable. Research priorities include correlates of protection, durability of immunity, subgroup safety, and the role of booster doses.
引用
- Tan CS, Anjan S, Ariza-Heredia EJ, et al. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026. PMID: 41766598. doi:10.1093/cid/ciag117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。